By using DiabetesTimes.co.uk, you agree to our terms and use of cookies to enhance your experience.
Diabetes support programme relaunches to help plug COVID-19 hole in diabetes clinics Healthcare professionals can now refer people prescribed Toujeo onto a coaching programme to ensure they ...
Toujeo® (insulin glargine 300 units/mL) can now be used to treat children and teenagers with type 1 diabetes, pharmaceutical giant Sanofi has announced. The European Commission (EC) has approved ...
Children and adolescents with type 1 diabetes achieved comparable reduction in HbA1c and similar risk of low blood sugar events with Toujeo® (insulin glargine 300 Units/mL) compared to insulin ...
Heroes from the diabetes community were rewarded at the ninth annual Quality in Care (QiC) Diabetes Awards. More than 100 people attended the ceremony, which took place on the evening of ...
Sanofi has this week announced the UK launch of Suliqua™ (insulin glargine/lixisenatide) for the treatment of adults with type 2 diabetes. The drug is a once-daily, titratable, fixed-ratio ...
Abbott and Sanofi are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition, it has been ...
Sanofi has launched a new long-acting insulin glargine injection pen recommended for adults with type 1 or type 2 diabetes mellitus requiring at least 20 units of basal insulin per day. The ...
Global life sciences company Sanofi has pledged 10 million euros towards the rebuilding of Notre Dame after last week’s devastating fire. The Paris skyline was changed when a blaze tore ...
The deadline to nominate a healthcare professional for a major award is looming. Colleagues are being encouraged to submit an entry to the Quality in Care Diabetes (QiC) awards by Friday, July ...
Sanofi has presented results from the first head-to-head study comparing Toujeo® (insulin glargine 300 units/mL (Gla-300)) to insulin degludec. Gla-300 met primary endpoint in lowering blood ...